MYC and cancer: In parallel, although MYC dosage compensation has emerged as a promising therapeutic target for various aneuploid cancers with increased MYC copy numbers, its effective targeting is limited by the lack of robust cellular models to test candidate molecules capable of disrupting this compensatory mechanism.